Wettig Thane's Insider Trades & SAST Disclosures
Wettig Thane's most recent trade in FibroGen Inc was a trade of 145,000 Common Stock done at an average price of $0.3 . Disclosure was reported to the exchange on March 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Wettig Thane.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| FibroGen Inc | Thane Wettig | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.35 per share. | 24 Mar 2025 | 145,000 | 543,329 (0%) | 0% | 0.3 | 50,663 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 22,038 | 397,915 (0%) | 0% | 0.4 | 8,595 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 781 | 398,696 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 367 | 398,329 (0%) | 0% | 0.4 | 143 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 06 Dec 2024 | 2,363 | 419,953 (0%) | 0% | 0.3 | 808 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Sep 2024 | 2,363 | 422,316 (0%) | 0% | 0.4 | 922 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 01 Aug 2024 | 20,840 | 424,679 (0%) | 0% | 0.5 | 9,795 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 22 Jun 2024 | 782 | 445,519 (0%) | 0% | 1.1 | 884 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 06 Jun 2024 | 2,255 | 446,301 (0%) | 0% | 1.2 | 2,683 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.17 per share. | 01 May 2024 | 20,840 | 448,556 (0%) | 0% | 1.2 | 24,383 | Common Stock |
| FibroGen Inc | Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 22 Mar 2024 | 782 | 469,396 (0%) | 0% | 2.6 | 2,018 | Common Stock |
| FibroGen Inc | Thane Wettig | CEO | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 07 Mar 2024 | 50,000 | 470,178 (0%) | 0% | 1.9 | 95,470 | Common Stock |
| FibroGen Inc | Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 4,209 | 419,723 (0%) | 0% | 1.9 | 7,871 | Common Stock |
| FibroGen Inc | Thane Wettig | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 781 | 420,504 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 326 | 420,178 (0%) | 0% | 1.9 | 610 | Common Stock |
| FibroGen Inc | Wettig Thane | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 834,000 | 834,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 166,000 | 423,932 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Wettig Thane | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 01 Feb 2024 | 23,490 | 257,932 (0%) | 0% | 2.4 | 55,671 | Common Stock |
| FibroGen Inc | Wettig Thane | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 22 Dec 2023 | 819 | 281,422 (0%) | 0% | 0.8 | 622 | Common Stock |
| FibroGen Inc | Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. | 06 Dec 2023 | 1,680 | 282,241 (0%) | 0% | 0.6 | 974 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 200,000 | 308,261 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 16.53 per share. | 23 Jun 2023 | 791 | 108,261 (0%) | 0% | 16.5 | 13,075 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 1,286 | 109,052 (0%) | 0% | 17.0 | 21,910 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 472 | 110,338 (0%) | 0% | 17.0 | 8,041 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.71 per share. | 23 Mar 2023 | 905 | 110,653 (0%) | 0% | 18.7 | 16,933 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2023 | 2,343 | 108,310 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2023 | 1,000 | 1,000 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 9,338 | 119,227 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 08 Mar 2023 | 6,265 | 104,090 (0%) | 0% | 21.2 | 132,542 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 5,799 | 109,889 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 4,731 | 111,558 (0%) | 0% | 20.2 | 95,553 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 2,938 | 116,289 (0%) | 0% | 20.2 | 59,340 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 25,000 | 110,355 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 1,988 | 87,175 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 15.80 per share. | 23 Dec 2022 | 734 | 89,163 (0%) | 0% | 15.8 | 11,597 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 22 Sep 2022 | 655 | 90,279 (0%) | 0% | 12.3 | 8,030 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 06 Sep 2022 | 360 | 90,934 (0%) | 0% | 12.3 | 4,414 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.42 per share. | 22 Jun 2022 | 655 | 91,294 (0%) | 0% | 11.4 | 7,480 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 06 Jun 2022 | 360 | 89,961 (0%) | 0% | 9.5 | 3,420 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 22 Mar 2022 | 655 | 90,321 (0%) | 0% | 13.3 | 8,718 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 07 Mar 2022 | 1,706 | 90,976 (0%) | 0% | 12.7 | 21,649 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 45,000 | 92,682 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.97 per share. | 22 Dec 2021 | 517 | 47,682 (0%) | 0% | 15.0 | 7,739 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.18 per share. | 22 Sep 2021 | 620 | 48,196 (0%) | 0% | 10.2 | 6,312 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 11.53 per share. | 26 Aug 2021 | 3,100 | 48,816 (0%) | 0% | 11.5 | 35,743 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.65 per share. | 22 Jun 2021 | 2,593 | 45,716 (0%) | 0% | 27.6 | 71,696 | Common Stock |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 32,100 | 32,100 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 16,500 | 47,150 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 30,000 | 30,600 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges